share_log

Delivra Health Brands Announces Grant of Incentive Stock Options

newsfile ·  May 29 05:15

Vancouver, British Columbia--(Newsfile Corp. - May 28, 2024) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce that pursuant to a resolution passed by the Company's Board of Directors on May 28, 2024, it has granted an aggregate of 14,000,000 incentive stock options (the "Options") under the Company's 10% fixed stock option plan, to certain directors, officers and employees of the Company. The Options are exercisable at a price of $0.05 per common share, will have a term of five years from the date of grant, and will vest 1/3 annually from the date of grant. The Options are subject to the terms and conditions prescribed by the TSX Venture Exchange, and applicable securities laws.

About Delivra Health Brands Inc.

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water and LivRelief, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are Dream Water and LivReliefTM. For more information, please visit .

Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment